Prebiopsy MRI can ‘transform’ prostate cancer care, study finds August 27, 2019 Prebiopsy multiparametric MRI (mpMRI) paired with targeted biopsy can improve the detection of clinically significant prostate cancer, according to a study published in JAMA Network Open.Identifying high-risk from low-risk prostate cancers can spare men from unnecessary invasive treatments and treatment-associated morbidity, wrote first author Martha M. C. Elwenspoek, PhD, but doing so remains difficult.“There is, therefore, an unmet clinical need to develop tests that can detect clinically significant PCa (csPCa) while reducing overdiagnosis of low-risk disease,” Elwenspoek, with the University of Bristol in the UK, and colleagues noted.Read the full article here.Source: Matt O'Connor - Health Imaging Prostate Cancer News
Prebiopsy multiparametric MRI (mpMRI) paired with targeted biopsy can improve the detection of clinically significant prostate cancer, according to a study published in JAMA Network Open.Identifying high-risk from low-risk prostate cancers can spare men from unnecessary invasive treatments and treatment-associated morbidity, wrote first author Martha M. C. Elwenspoek, PhD, but doing so remains difficult.“There is, therefore, an unmet clinical need to develop tests that can detect clinically significant PCa (csPCa) while reducing overdiagnosis of low-risk disease,” Elwenspoek, with the University of Bristol in the UK, and colleagues noted.Read the full article here.Source: Matt O'Connor - Health Imaging
